Journal of Vaccine Research 2024, Vol.14, No.5, 269-277 http://medscipublisher.com/index.php/jvr 276 McFadyen I., Moore M.J., Senn J.J., Stanton M.G., Almarsson Ö., Giuseppe Ciaramella G., and Brito, L.A., 2019, Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines, Molecular Therapy, 27(9), 1912-1921. https://doi.org/10.1016/j.ymthe.2019.07.013 PMID: 30785039 PMCID: PMC6383180 Hou X., Zaks T., Langer R., and Dong Y., 2021, Lipid nanoparticles for mRNA delivery, Nature Reviews Materials, 6(12): 1078-1094. https://doi.org/10.1038/s41578-021-00358-0 Jackson L.A., Anderson E.J., Rouphael, N. G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., McDermott A., Flach B., Doria-Rose N.A., Corbett K.S., Morabito K.M.M., O’Dell S., Schmidt S.D., Swanson P.A., Padilla M., Mascola J.R., Neuzil K.M., Bennett H., Sun W., Peters E., Makowski M., Albert J., Kaitlyn Cross K., Buchanan W., Pikaart-Tautges R., Ledgerwood J.E., Graham B.S., Beigel J.H., and the mRNA-1273 Study Group, 2020, An mRNA vaccine against SARS-CoV-2-Preliminary report, The New England Journal of Medicine, 383(20): 1920-1931. https://doi.org/10.1056/NEJMoa2022483 Krammer F., 2020, SARS-CoV-2 vaccines in development, Nature, 586(7830): 516-527. https://doi.org/10.1038/s41586-020-2798-3 Hafner T., Popp D., and Zhang J., 2020, COVID-19 vaccines and intellectual property: recommendations for equity and global access, Health Affairs, 39(9): 1608-1614. https://doi.org/10.1377/hlthaff.2020.01229 Karikó K., Muramatsu H., and Weissman D., 2015, Increased immune activation of nucleoside-modified mRNA for vaccine delivery, Cell, 162(5): 931-943. https://doi.org/10.1016/j.cell.2015.07.017 Kranz L.M., Diken M., Haas H., Kreiter S., Loquai C., Reuter K.C., Meng M., Fritz D., Vascotto F., Hefesha H., Grunwitz C., Vormehr M., Hüsemann Y., Selmi A., Kuhn A.N.,Buck J., Derhovanessian E., Rae R., Sebastian Attig S., Diekmann J., Jabulowsky R.A., Heesch S., Jessica Hassel J., Langguth P., Stephan Grabbe S., Christoph Huber C., Türeci Ö., and Sahin U., 2016, Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy, Nature, 534(7607): 396-401. https://doi.org/10.1038/nature18300 PMID: 27281205 Mevorach D., Anis E., Cedar N., Bromberg, M., Haas, E. J., Nadir, E., Olsha-Castell S., Arad D., Hasin T., Levi N., Asleh R., Amir O., Meir K., Cohen D., Dichtiar R., Novick D., Hershkovitz Y., Dagan R., Leitersdorf I., Ben-Ami R., Miskin I., Saliba W., Muhsen K., Levi Y., Green M.S., Keinan-Boker L., and Alroy-Preis S., 2021, Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel, The New England Journal of Medicine, 385(23): 2140-2149. https://doi.org/10.1056/NEJMoa2109730 PMID: 34614328 PMCID: PMC8531987 Moon S., Armstrong J., Hutler B., and Upshur R., 2021, COVAX and global equity: what can we learn from the past?, Globalization and Health, 17(1): 1-6. https://doi.org/10.1186/s12992-021-00712-2 Pardi N., Hogan M.J., Porter F.W., and Weissman D., 2018, mRNA vaccines-A new era in vaccinology, Nature Reviews Drug Discovery, 17(4): 261-279. https://doi.org/10.1038/nrd.2017.243 PMID: 29326426 PMCID: PMC5906799 Phelan A.L., Eccleston-Turner M., Rourke M., Maleche A., and Wang C.G., 2021, Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access, The Lancet, 398(10297): 358-364. https://doi.org/10.1016/S0140-6736(21)00922-3 PMID: 32910908 PMCID: PMC7832682 Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck Jr R.W., Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U., Gruber W.C., and C4591001 Clinical Trial Group, 2020, Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine, The New England Journal of Medicine, 383(27): 2603-2615. https://doi.org/10.1056/NEJMoa2034577 PMID: 33301246 PMCID: PMC7745181 Rauch S., Jasny E., Schmidt K.E., and Petsch B., 2018, New vaccine technologies to combat outbreak situations, Frontiers in Immunology, 9: 1963. https://doi.org/10.3389/fimmu.2018.01963 PMID: 30283434 PMCID: PMC6156540 Roldão A., Picanço-Castro V., and Lobe M., 2021, Advances in non-viral mRNA delivery systems for vaccine applications, Frontiers in Bioengineering and Biotechnology, 9: 660085. https://doi.org/10.3389/fbioe.2021.660085 Sahin U., and Türeci Ö., 2017, Personalized vaccines for cancer immunotherapy, Science, 359(6382): 1355-1360. https://doi.org/10.1126/science.aar7112 PMID: 29567706 Sahin U., Muik A., Derhovanessian E., Vogler I., Kranz L.M., Vormehr M., Baum A., Pascal K., Quandt J., Maurus D., Brachtendorf S., Verena Lörks V., Sikorski J., Hilker R., Becker D., Eller A.K, Grützner J., Boesler C., Rosenbaum C., Kühnle M.C., Luxemburger U., Kemmer-Brück A., Langer D., Bexon M., Bolte S., Karikó K., Tania Palanche T., Fischer B., Schultz A., Shi P.Y., Fontes-Garfias C., Perez J.L., Swanson K.A., Loschko J.L., Scully I.L., Cutler
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==